Roger Stupp

TL;DR: This first in patient application of OXY111A will reveal potential beneficial outcomes if anti-hypoxic therapy is added to standard cytotoxic treatment in patients with primary and secondary hepatopancreatobiliary tumors.

TL;DR: The brain target volume receiving focal radiation therapy did not appear to be independently associated with HRQoL in high-risk patients with low-grade glioma in the short term, as opposed to tumor progression.

TL;DR: An integrated multidisciplinary group of authors proposes a novel next-generation treatment paradigm based on the targeting of multiple hallmarks of cancer evolution that will heavily rely on MI.

TL;DR: The saga of bevacizumab in brain tumors has been ongoing for many years, and despite encouraging initial reports targeting the vascular endothelial growth factor pathway by a neutralizing monoclonal antibody or a receptor tyrosine kinase inhibitor, the few subsequent controlled studies were largely disappointing.

TL;DR: Both methodologies are complementary, with a higher sensitivity for HM450 and a far larger genome-wide coverage for MethylCap-seq, but also that a more comprehensive character does not automatically imply more significant results in biomarker studies.